Can using a CPAP lower mortality risk from sleep apnea–related heart disease?

Continuous positive airway pressure (CPAP) is a standard treatment for obstructive sleep apnoea (OSA). Research suggests effective CPAP use may reduce cardiovascular complications linked to untreated OSA. In this episode, we explain the evidence and how sleep apnoea is assessed in Europe.

In this episode, we cover:

• What obstructive sleep apnoea is (repeated airway collapse during sleep)

• How OSA increases cardiovascular risk (hypertension, arrhythmias, stroke)

• The role of intermittent hypoxia and sympathetic activation

• How CPAP maintains airway patency

• Evidence on cardiovascular outcomes and mortality

• CPAP adherence and effectiveness

• When sleep studies (polysomnography or home testing) are required

• When in-person cardiology or respiratory review is necessary

Doctors assess symptoms (snoring, witnessed apnoea, daytime sleepiness), BMI, blood pressure, arrhythmia history, and cardiovascular risk before recommending sleep testing. CPAP requires formal diagnosis and fitting. Untreated severe OSA, chest pain, or arrhythmia symptoms require in-person evaluation.

This episode reflects how sleep and cardiovascular risk are reviewed within structured medical assessment in European telemedicine at Mobi Doctor.

Read the full medical guide here:

https://www.mobidoctor.eu/blog/using-a-cpap-may-lower-mortality-risk-from-sleep-apnea-related-heart-disease